News

In a presentation at the American Society of Retina Specialists 2022 annual meeting at the Jacob K. Javits Convention Center in New York, Yoshihiro Yonekawa, MD, detailed that primary scleral buckling achieved the best visual acuity, and pointed out that rhegmatogenous detachments increased with age.

Rhegmatogenous detachments increased with age; myopia, trauma, and history of retinopathy were common underlying risk factors for development of rhegmatogenous retinal detachments.

In the TENAYA and LUCERNE studies, more than 60% of faricimab patients could be treated every 4 months at 2 years, an increase from 45% at year 1. Study results are being presented at the American Society of Retina Specialists 2022 annual meeting in New York.

Treatment with faricimab in patients with neovascular AMD achieved improvements in the visual acuity, central subfield thickness, and pigment epithelial detachments.

Topics spanned from faricimab in nAMD and DME; pediatric retinal detachment surgery; and the relationship between outer retinal integrity and subretinal fluid.

Mount Sinai study is among the first to link cardiovascular risk to a specific form of age-related macular degeneration.

The program — entitled “Pumping Adrenaline!” — brings viewers myriad challenging cases, intraoperative complications, and complex problems following cataract surgery.

The University of Oklahoma Health Sciences Center has received an unrestricted grant from Research to Prevent Blindness for $575,000 over 5 years to support eye research conducted by the Department of Ophthalmology.

Charles Brodowski, MD, and Patrick Rapuano, MD, have been named co-chief residents at Wills Eye Hospital, and will lead the team of resident doctors on staff, focusing on training and recruitment while attending to their own medical resident duties.

Results from our recent poll regarding ASRS 2022 attendance indicate that most ophthalmologists and retina specialists plan to participate in the Annual Meeting in person in New York, New York.

According to investigators, patients with age-related macular degeneration like the port delivery system for ranibizumab because it requires fewer treatments and there is less discomfort.

Kala Pharmaceuticals Inc. announced that it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was first announced in May.

CAM encourages corneal healing in patients with ocular surface disease.

A team of investigators at the Agency for Science, Technology and Research in Singapore have developed a bio-functional thermogel, a type of synthetic polymer, to prevent retinal scarring caused by failed retinal detachment repair surgery.

According to William B. Trattler, MD, progression of the disease before cross-linking often can be identified over a period of months.

Kiora Pharmaceuticals announced it has enrolled the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with PCED, a rare ocular surface condition characterized by non-healing wounds on the eye surface.

A team of investigators from Johns Hopkins Medicine say they’ve discovered that levels of a specific protein appears to help accurately predict whether people with the wet form of age-related macular degeneration may need lifelong, frequent eye injections to preserve vision or if they can be safely weaned off the treatments.

According to Mark Lobanoff, DO, earlier treatment also can mean the best possible results for patients.

The 40th annual scientific meeting of the American Society of Retina Specialists will be held July 13-16 at the Jacob K. Javits Convention Center in New York.

Researchers at the University of Bristol, as part of a 10-year follow-up study, found that severe “brain bleeds” experienced by some babies in the first year following their birth lead to long-term sight problems.

Lloyd Clark, MD, highlights his ASRS presentation focusing on the PANORAMA study detailing the use of aflibercept in the management of diabetic retinopathy.

CMS is proposing to cut the Medicare conversion factor—the basic starting point for calculating Medicare payments—by 4.42% for CY2023.

A team of investigators form Johns Hopkins Medicine say they’ve discovered that levels of a specific protein appears to help accurately predict whether people with the wet form of age-related macular degeneration may need lifelong, frequent eye injections to preserve vision or if they can be safely weaned off the treatments.

The 40th annual Scientific Meeting of the American Society of Retina Specialists is scheduled for July 13-16, 2022, in New York City, New York, United States.

NOV03 is an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction.

Foundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.

Researchers at the University of Bristol, as part of a 10-year follow-up study, found that severe “brain bleeds” experienced by some babies in the first year following their birth lead to long-term sight problems.

Kiora Pharmaceuticals announced it has enrolled the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with PCED, a rare ocular surface condition characterized by non-healing wounds on the eye surface.